TCP
ELDN icon

Tourbillon Capital Partners’s Eledon Pharmaceuticals ELDN Stock Holding History

Tourbillon Capital Partners’s Portfolio ELDN Stock Details ELDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-3,191
Closed -$6.88M – 105
2015
Q2 		$6.88M Hold
3,191
– – 0.15% 89
2015
Q1 		$5.84M Hold
3,191
– – 0.15% 66
2014
Q4 		$7.62M Buy
3,191
+228
+8% +$541K 0.21% 78
2014
Q3 		$7.27M Buy
+2,963
New +$8.42M 0.26% 67

Other funds holding ELDN

NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
KCM
Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Tourbillon Capital Partners's ELDN Position: Q3 2015 in Review

Tourbillon Capital Partners sold out of Eledon Pharmaceuticals (ELDN) in Q3 2015, closing a stake of 3,191 shares — an estimated $6.88M sold.

Tourbillon Capital Partners first reported a position in ELDN in Q3 2014 and held it in 4 quarters. The position peaked at $7.62M in Q4 2014. 49 funds tracked by Wall St. Rank hold ELDN as of Q3 2015.

  • Tourbillon Capital Partners reported no remaining Eledon Pharmaceuticals position as of Q3 2015 after selling out during the quarter.
  • Tourbillon Capital Partners sold 3,191 Eledon Pharmaceuticals shares in Q3 2015, an estimated $6.88M.
  • Tourbillon Capital Partners first reported a position in Eledon Pharmaceuticals in Q3 2014 and held it in 4 quarters.
  • Tourbillon Capital Partners's Eledon Pharmaceuticals position peaked at $7.62M in Q4 2014.
  • 49 funds tracked by Wall St. Rank held Eledon Pharmaceuticals as of Q3 2015.

Based on Tourbillon Capital Partners's 13F filing for Q3 2015, filed 16 Nov 2015.